A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)
Latest Information Update: 11 Jun 2025
At a glance
- Drugs CMG 901 (Primary) ; Docetaxel; Irinotecan; Paclitaxel; Ramucirumab; Rivoceranib; Tipiracil/trifluridine
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CLARITY Gastric 01
- Sponsors AstraZeneca; KeyMed Biosciences
Most Recent Events
- 04 Jun 2025 Planned number of patients changed from 589 to 572.
- 03 May 2022 New trial record